Literature DB >> 1874565

Interleukin 6 is secreted by breast fibroblasts and stimulates 17 beta-oestradiol oxidoreductase activity of MCF-7 cells: possible paracrine regulation of breast 17 beta-oestradiol levels.

E F Adams1, B Rafferty, M C White.   

Abstract

Previous studies have demonstrated that cultured human breast fibroblasts secrete a high-molecular-weight polypeptide which stimulates the ability of human breast-cancer MCF-7 cells to convert oestrone (E1) to the biologically more active 17 beta-oestradiol (E2). This effect is mediated by an increase in reductive E2 oxidoreductase (EOR) activity. We have identified the fibroblast-derived stimulatory factor as interleukin 6 (IL6) or an immunologically related peptide. Human breast fibroblasts in culture secreted up to 10 ng IL6/ml medium during 24 hr of incubation. The effects of IL6 and breast fibroblast conditioned medium (CM) on reductive EOR activity of MCF-7 cells were similar; both CM and IL6 potently stimulated enzyme activity in a dose-dependent manner, and both exerted synergistic stimulatory effects in combination with E2. A polyclonal neutralizing antibody to IL6 completely abolished the reductive EOR-stimulating activity of CM. These results indicate that breast stromal fibroblasts may have a paracrine role in regulation of breast-cancer-tissue levels of E2, and that this effect is mediated by IL6 or a closely related peptide.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1874565     DOI: 10.1002/ijc.2910490122

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Estrogen metabolism as a regulator of estrogen action in the mammary gland.

Authors:  M Miettinen; V Isomaa; H Peltoketo; D Ghosh; P Vihko
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

2.  Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk.

Authors:  Mia M Gaudet; Kathleen M Egan; Jolanta Lissowska; Polly A Newcomb; Louise A Brinton; Linda Titus-Ernstoff; Meredith Yeager; Stephen Chanock; Robert Welch; Beata Peplonska; Amy Trentham-Dietz; Montserrat Garcia-Closas
Journal:  Hum Genet       Date:  2007-01-11       Impact factor: 4.132

3.  Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer.

Authors:  Margaret M Madeleine; Lisa G Johnson; Mari Malkki; Alexa J Resler; Effie W Petersdorf; Barbara McKnight; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2011-04-27       Impact factor: 4.872

Review 4.  The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer.

Authors:  Atul Purohit; Simon P Newman; Michael J Reed
Journal:  Breast Cancer Res       Date:  2002-01-14       Impact factor: 6.466

5.  Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours.

Authors:  V Speirs; S L Atkin
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

6.  In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.

Authors:  V Speirs; D S Walton; M C Hall; S L Atkin
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

Review 7.  Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity.

Authors:  Alexander E Davies; John G Albeck
Journal:  Front Cell Dev Biol       Date:  2018-04-20

8.  Proliferative behaviour of an oestrogen sensitive rat mammary tumour: evidence for a paracrine interaction between tumour and stroma.

Authors:  M G Ormerod; J C Titley; T A Smith; A L Tombs; S Eccles
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

9.  Activity of interferon alpha, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cells.

Authors:  C McCormick; R I Freshney; V Speirs
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.